公开(公告)号：US20130318644A1

公开(公告)日：2013-11-28

申请号：US13979887

申请日：2012-01-17

Applicant: Aaron Marshall ,  Sen Hou

Inventor： Aaron Marshall ,  Sen Hou

IPC: A61K38/17

CPC classification number: C07K14/435 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/058 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K38/00 ,  A61K38/1709 ,  C07K14/001 ,  G01N33/5088 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4721 ,  G01N2500/00 ,  G01N2500/10 ,  G01N2800/18 ,  G01N2800/347

Abstract: Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes

Abstract translation: 本文提供FDC-SP多肽和使用这些多肽的方法。 方法包括但不限于改变受试者中的IgA浓度，治疗具有包括过量IgA产生的病症征象的受试者，鉴定降低动物中IgA浓度的化合物，以及鉴定治疗 与IgA水平升高相关的病症。 本文还提供具有降低的内源性FDC-SP编码序列的表达的动物。 该动物可能发展IgA肾病的病理生理学特征，和/或可能在血清，唾液，支气管肺泡灌洗液或其组合中显示增加的IgA; 循环中增加的IgA表达B淋巴细胞，淋巴组织或其组合; 或通过分离的B淋巴细胞在体外增加IgA产生

公开(公告)号：US20130185819A1

公开(公告)日：2013-07-18

申请号：US13793812

申请日：2013-03-11

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Lynn MACDONALD ,  Andrew J. MURPHY ,  Cagan GURER ,  John MCWHIRTER ,  Vera VORONINA ,  Faith HARRIS ,  Sean STEVENS ,  Yingzi XUE

IPC: A01K67/027

CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0387

Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

Abstract translation: 本发明提供表达嵌合人/非人MHC I多肽和/或人或人源化β2微球蛋白多肽以及包含其的胚胎，细胞和组织的遗传修饰的非人动物。 还提供了用于制备所述转基因动物的构建体及其制备方法。 提供了使用遗传修饰动物研究人体免疫系统各个方面的方法。

公开(公告)号：US20130115226A1

公开(公告)日：2013-05-09

申请号：US13643171

申请日：2011-04-28

Applicant: Paul Van Slyke ,  Daniel Dumont

Inventor： Paul Van Slyke ,  Daniel Dumont

IPC: A61K38/08 ,  A61K38/17

CPC classification number: A61K38/08 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/203 ,  A01K2227/105 ,  A01K2267/0368 ,  A01K2267/0387 ,  A61K38/17 ,  A61K38/1891 ,  A61K38/39 ,  A61K47/60 ,  A61K48/005 ,  C07K7/06 ,  C07K14/475 ,  C07K14/515

Abstract: The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels.

Abstract translation: 本公开提供了Tie2结合和/或活化剂的方法和用途。 特别地，本公开提供了用于抑制集落形成单位粒细胞，减少嗜酸性粒细胞和/或嗜碱性粒细胞扩增的方法和用途，用于治疗过敏性疾病或反应或嗜酸性粒细胞/嗜碱性粒细胞相关病症并减少炎性细胞因子和/或趋化因子水平 。

公开(公告)号：US20130109053A1

公开(公告)日：2013-05-02

申请号：US13661342

申请日：2012-10-26

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn MACDONALD ,  Andrew J. MURPHY ,  John MCWHIRTER ,  Naxin TU ,  Vera VORONINA ,  Cagan GURER ,  Karolina MEAGHER ,  Sean STEVENS

IPC: A01K67/027 ,  C12P21/00 ,  A01K67/02

CPC classification number: A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0387 ,  C07K14/7051 ,  C07K2319/00 ,  C12N15/8509 ,  C12N2800/204 ,  C12N2800/30

Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.

Abstract translation: 本发明提供了一种遗传修饰的非人动物，其在其基因组中包含未经修复的T细胞受体可变基因基因座，以及胚胎，细胞和包含该基因的组织。 还提供了用于制备所述转基因非人动物的构建体及其制备方法。 还提供了使用转基因非人动物的各种方法。

公开(公告)号：US20120252051A1

公开(公告)日：2012-10-04

申请号：US13434805

申请日：2012-03-29

Applicant: Franck Barrat ,  Robert L. Coffman ,  Cristiana Guiducci

Inventor： Franck Barrat ,  Robert L. Coffman ,  Cristiana Guiducci

IPC: A01K67/027 ,  C12Q1/02 ,  C12N5/10

CPC classification number: G01N33/5073 ,  A01K67/0271 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0387 ,  C07K14/705 ,  C07K14/70596 ,  C12N5/0647 ,  C12N2510/00 ,  G01N33/502 ,  G01N33/5023 ,  G01N33/5038

Abstract: Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof.

Abstract translation: 本文提供了表达转基因动物的人Toll样受体8（TLR8）及其使用方法。

公开(公告)号：US20120177635A1

公开(公告)日：2012-07-12

申请号：US13281209

申请日：2011-10-25

Applicant: LAWREN WU ,  MERCEDESZ BALAZS ,  HANS BRIGHTBILL ,  ANDY CHAN ,  YVONNE CHEN ,  ANAN CHUNTHARAPAL ,  MARK DENNIS ,  TERENCE WONG

Inventor： LAWREN WU ,  MERCEDESZ BALAZS ,  HANS BRIGHTBILL ,  ANDY CHAN ,  YVONNE CHEN ,  ANAN CHUNTHARAPAL ,  MARK DENNIS ,  TERENCE WONG

IPC: A61K39/395

CPC classification number: C07K16/4291 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73

Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Abstract translation: 本申请涉及凋亡性抗IgE抗体，编码它的核酸，其治疗组合物及其在治疗IgE介导的病症中的用途。

公开(公告)号：US08071097B2

公开(公告)日：2011-12-06

申请号：US12053063

申请日：2008-03-21

Applicant: Lawren Wu ,  Mercedesz Balazs ,  Hans Brightbill ,  Andrew Chan ,  Yvonne Chen ,  Anan Chuntharapai ,  Mark Dennis ,  Terence Wong

Inventor： Lawren Wu ,  Mercedesz Balazs ,  Hans Brightbill ,  Andrew Chan ,  Yvonne Chen ,  Anan Chuntharapai ,  Mark Dennis ,  Terence Wong

IPC: A61K39/395

CPC classification number: C07K16/4291 ,  A01K67/0278 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/0387 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/73

Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.

Abstract translation: 本申请涉及凋亡性抗IgE抗体，编码它的核酸，其治疗组合物及其在治疗IgE介导的病症中的用途。

公开(公告)号：US20110256556A1

公开(公告)日：2011-10-20

申请号：US13113677

申请日：2011-05-23

Applicant: Lynn Macdonald ,  Naxin Tu ,  Cagan Gurer ,  Li-Hsien Wang ,  Sean Stevens ,  Andrew J. Murphy

Inventor： Lynn Macdonald ,  Naxin Tu ,  Cagan Gurer ,  Li-Hsien Wang ,  Sean Stevens ,  Andrew J. Murphy

IPC: G01N33/574 ,  G01N33/567 ,  C12N5/00

CPC classification number: C07K14/70535 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0387 ,  G01N33/56977 ,  G01N2333/70535

Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.

Abstract translation: 提供了遗传修饰的非人动物以及用于制备和使用它们的方法和组合物，其中所述遗传修饰包括内源性低亲和力FcγR基因座的缺失，并且其中所述小鼠能够表达功能性FcRγ-链。 描述了转基因小鼠，包括从内源性FcγR基因座表达低亲和性人FcγR基因的小鼠，其中小鼠包含功能性FcRγ-链。 提供了在宿主免疫系统的辅助细胞上表达多达五个低亲和力的人FcγR基因的转基因小鼠。

公开(公告)号：US20110200982A1

公开(公告)日：2011-08-18

申请号：US12897517

申请日：2010-10-04

Applicant: Sean Stevens ,  Andrew J. Murphy ,  Richard Flavell ,  Elizabeth Eynon ,  Jorge Galan ,  Tim Willinger ,  Markus Manz ,  Anthony Rongvaux

Inventor： Sean Stevens ,  Andrew J. Murphy ,  Richard Flavell ,  Elizabeth Eynon ,  Jorge Galan ,  Tim Willinger ,  Markus Manz ,  Anthony Rongvaux

IPC: C12Q1/68 ,  A01K67/027 ,  C12Q1/70 ,  C12Q1/02

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0331 ,  A01K2267/0337 ,  A01K2267/0381 ,  A01K2267/0387 ,  A61K49/00 ,  C07K14/524 ,  C07K14/535 ,  C07K14/5403 ,  C07K14/7155 ,  C12N9/00

Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Abstract translation: 具有mIL-3基因和mGM-CSF基因的人源化的小鼠，mRAG基因的敲除和mIl2rg亚基基因的敲除; 并且可选地描述了TPO基因的人源化。 描述了RAG / Il2rg KO / hTPO敲入小鼠。 描述了维持人类免疫细胞（HIC）群体的人类造血干细胞（HSCs）的小鼠，所述人类免疫细胞（HIC）群体来自HSC并且可被人类病原体例如伤寒沙门氏菌或结核分枝杆菌感染。 描述了模拟在小鼠中模拟不良的人类病原体感染的小鼠，例如模拟人类分枝杆菌感染的小鼠，其中小鼠产生包含人免疫细胞的一种或多种肉芽肿。 描述了包含源于早期人类造血细胞的人类造血恶性肿瘤的小鼠，例如骨髓性白血病或骨髓增生性肿瘤。

公开(公告)号：US20110113496A1

公开(公告)日：2011-05-12

申请号：US12942666

申请日：2010-11-09

Applicant: LEONARD D. SHULTZ ,  DALE L. GREINER

Inventor： LEONARD D. SHULTZ ,  DALE L. GREINER

IPC: A01K67/027

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0387 ,  C12N15/8509

Abstract: Transgenic immunodeficient non-human animals according to embodiments of the present invention are described which include in their genome a nucleic acid encoding xenogeneic Stem Cell Factor operably linked to a promoter. Administration of xenogeneic hematopoetic stem cells to the inventive transgenic animals results in engraftment of the xenogeneic hematopoetic stem cells and xenogeneic leukocytes are produced in the animals, without conditioning such as without conditioning by irradiation and without conditioning by a radiomimetic agent.

Abstract translation: 描述了根据本发明实施方案的转基因免疫缺陷型非人动物，其在其基因组中包含编码与启动子可操作连接的异种干细胞因子的核酸。 将异种造血干细胞施用于本发明的转基因动物导致异种造血干细胞的移植，并且在动物中产生异种白细胞，而不进行调理，例如不经辐照调理而不用辐射拟肽剂调理。